Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Negative-strand RNA viral vectors: intravenous application of Sendai virus vectors for the systemic delivery of therapeutic genes.

Bitzer M, Ungerechts G, Bossow S, Graepler F, Sedlmeier R, Armeanu S, Bernloehr C, Spiegel M, Gross CD, Gregor M, Neubert WJ, Lauer UM.

Mol Ther. 2003 Feb;7(2):210-7.

2.

Efficient propagation of single gene deleted recombinant Sendai virus vectors.

Bernloehr C, Bossow S, Ungerechts G, Armeanu S, Neubert WJ, Lauer UM, Bitzer M.

Virus Res. 2004 Feb;99(2):193-7. Erratum in: Virus Res. 2004 May;101(2):205.

PMID:
14749185
3.

Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.

Schneider H, Mühle C, Douar AM, Waddington S, Jiang QJ, von der Mark K, Coutelle C, Rascher W.

J Gene Med. 2002 Jan-Feb;4(1):46-53.

PMID:
11828387
4.

Sendai virus vectors as an emerging negative-strand RNA viral vector system.

Bitzer M, Armeanu S, Lauer UM, Neubert WJ.

J Gene Med. 2003 Jul;5(7):543-53. Review.

PMID:
12825193
5.

High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors.

Miao CH, Ye X, Thompson AR.

Hum Gene Ther. 2003 Sep 20;14(14):1297-305.

PMID:
14503965
6.

Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero.

Chen XG, Zhu HZ, Gong JL, Li F, Xue JL.

Acta Pharmacol Sin. 2004 Jun;25(6):789-93.

7.

Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector.

Tsui LV, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, Moskalenko M, Mondesire J, Davis J, Roey MV, Dull T, McArthur JG.

Nat Biotechnol. 2002 Jan;20(1):53-7.

PMID:
11753362
8.

Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.

Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW.

Blood. 2001 Mar 1;97(5):1258-65.

9.
10.

Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells.

Wang JM, Zheng H, Sugahara Y, Tan J, Yao SN, Olson E, Kurachi K.

Hum Gene Ther. 1996 Sep 10;7(14):1743-56.

11.

Epstein-Barr virus vectors provide prolonged robust factor IX expression in mice.

Sclimenti CR, Neviaser AS, Baba EJ, Meuse L, Kay MA, Calos MP.

Biotechnol Prog. 2003 Jan-Feb;19(1):144-51.

PMID:
12573017
12.
13.
14.

Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.

Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1426-31.

15.

Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.

Nathwani AC, Davidoff AM, Hanawa H, Hu Y, Hoffer FA, Nikanorov A, Slaughter C, Ng CY, Zhou J, Lozier JN, Mandrell TD, Vanin EF, Nienhuis AW.

Blood. 2002 Sep 1;100(5):1662-9.

16.

Genetic modification of bone-marrow mesenchymal stem cells and hematopoietic cells with human coagulation factor IX-expressing plasmids.

Sam MR, Azadbakhsh AS, Farokhi F, Rezazadeh K, Sam S, Zomorodipour A, Haddad-Mashadrizeh A, Delirezh N, Mokarizadeh A.

Biologicals. 2016 May;44(3):170-7. doi: 10.1016/j.biologicals.2016.01.002.

PMID:
26928674
17.

Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus.

Waddington SN, Buckley SM, Bernloehr C, Bossow S, Ungerechts G, Cook T, Gregory L, Rahim A, Themis M, Neubert WJ, Coutelle C, Lauer UM, Bitzer M.

Gene Ther. 2004 Apr;11(7):599-608.

PMID:
14724676
18.
20.

Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.

Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S, Matsushita T, Allen J, Surosky R, Lochrie M, Meuse L, McClelland A, Colosi P, Kay MA.

Blood. 2003 Oct 1;102(7):2412-9.

Supplemental Content

Support Center